- Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
- Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
- Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
Key statistics
On Wednesday, Quince Therapeutics Inc (QNCX:NSQ) closed at 0.7007, 10.68% above the 52 week low of 0.6331 set on Jun 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.70 |
---|---|
High | 0.75 |
Low | 0.70 |
Bid | 0.7357 |
Offer | 0.75 |
Previous close | 0.7375 |
Average volume | 65.53k |
---|---|
Shares outstanding | 43.22m |
Free float | 37.51m |
P/E (TTM) | -- |
Market cap | 31.87m USD |
EPS (TTM) | -0.7599 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼